Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis

被引:37
|
作者
Fan, Mengying [1 ]
Lin, Yao [1 ]
Pan, Jianhong [1 ]
Yan, Wanpu [1 ]
Dai, Liang [1 ]
Shen, Luyan [1 ]
Chen, Keneng [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Thorac Surg 1,Key Lab Carcinogenesis & Trans, Beijing 100142, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Esophageal cancer; induction chemoradiotherapy; induction chemotherapy; overall survival; CHEMORADIATION; STRATEGIES; MORTALITY;
D O I
10.1111/1759-7714.12299
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe efficacy of surgery alone for patients with locally advanced esophageal cancer (EC) is still unsatisfactory. Presently, induction therapy followed by surgery is the standard treatment. Preoperative chemotherapy (CT) and chemoradiation (CRT) are proven effective induction therapies; however, few sample studies have addressed these treatments, thus, their superiority remains uncertain. We performed a systemic review and meta analysis to test the hypothesis that induction CRT prior to surgery could improve survival compared with induction CT alone. MethodsA comprehensive search of PubMed and the Ovid database for relevant studies comparing EC patients undergoing resection after treatment with induction CT alone or induction CRT was conducted. Hazard ratios (HR) and 95% confidence intervals (95% CI) were extracted from these studies to provide pooled estimates of the effect of induction therapy on overall survival. ResultsFive studies met the criteria for analysis. Statistical analysis demonstrated a survival benefit of induction CRT compared with induction CT alone (HR0.73, 95% CI 0.61-0.89; P = 0.002). Further analysis showed that induction CRT perioperative mortality and complication rates were higher than for induction CT alone (HR 2.96, 95% CI 1.38-6.37; HR1.6, 95% CI 1.30-1.98; P = 0.01, respectively). ConclusionsPublished evidence comparing the different efficacies of induction CT and induction CRT is sparse, with few samples of adenocarcinoma. This analysis supports the view that, compared with induction CT, induction CRT could achieve a long-term survival benefit in EC patients.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 50 条
  • [21] Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis
    Zhu, Youqi
    Chen, Jiuzhou
    Sun, Xueqing
    Lou, Yufei
    Fang, Miao
    Zhou, Fengjuan
    Zhang, Lei
    Xin, Yong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
    Huaqin Lin
    Lei Wang
    Xiaohong Zhong
    Xueqing Zhang
    Lingdong Shao
    Junxin Wu
    World Journal of Surgical Oncology, 19
  • [23] Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
    Lin, Huaqin
    Wang, Lei
    Zhong, Xiaohong
    Zhang, Xueqing
    Shao, Lingdong
    Wu, Junxin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [24] Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
    Chen, Jiuzhou
    Guo, Yaru
    Fang, Miao
    Yuan, Yan
    Zhu, Youqi
    Xin, Yong
    Zhang, Longzhen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma A Network Meta-analysis
    Pasquali, Sandro
    Yim, Guang
    Vohra, Ravinder S.
    Mocellin, Simone
    Nyanhongo, Donald
    Marriott, Paul
    Geh, Ju Ian
    Griffiths, Ewen A.
    ANNALS OF SURGERY, 2017, 265 (03) : 481 - 491
  • [26] Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
    Chen, Yan
    Shi, Xiu-E
    Tian, Jin-Hui
    Yang, Xu-Juan
    Wang, Yong-Feng
    Yang, Ke-Hu
    MEDICINE, 2018, 97 (20)
  • [27] Comparison of esophageal cancer survival after neoadjuvant chemoradiotherapy plus surgery versus definitive chemoradiotherapy: A systematic review and meta-analysis
    Ke, Junli
    Xie, Yujie
    Huang, Shenyang
    Wang, Wei
    Zhao, Zhengang
    Lin, Wanli
    ASIAN JOURNAL OF SURGERY, 2024, 47 (09) : 3827 - 3840
  • [28] Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
    Wang, He
    Li, Sihan
    Liu, Tingting
    Chen, Jun
    Dang, Jun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma
    Nakashima, Yuichiro
    Saeki, Hiroshi
    Hu, Qingjiang
    Tsuda, Yasuo
    Hisamatsu, Yuichi
    Ando, Koji
    Oki, Eiji
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2018, 38 (12) : 6809 - 6814
  • [30] Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
    Faron, Matthieu
    Cheugoua-Zanetsie, Maurice
    Tierney, Jayne
    Thirion, Pierre
    Nankivell, Matthew
    Winter, Kathryn
    Yang, Hong
    Shapiro, Joel
    Vernerey, Dewi
    Smithers, B. Mark
    Walsh, Thomas
    Piessen, Guillaume
    Nilsson, Magnus
    Boonstra, Jurjen
    Ychou, Marc
    Law, Simon
    Cunningham, David
    de Vathaire, Florent
    Stahl, Michael
    Urba, Susan
    Valmasoni, Michele
    Williaume, Daniele
    Thomas, Janine
    Lordick, Florian
    Tepper, Joel
    Roth, Jack
    Gebski, Val
    Burmeister, Bryan
    Paoletti, Xavier
    van Sandick, Johanna
    Fu, Jianhua
    Pignon, Jean-Pierre
    Ducreux, Michel
    Michiels, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (28) : 4535 - +